HOME >> BIOLOGY >> NEWS
Abgenix reports positive clinical data with ABX-IL8 in Psoriasis

Improvement Seen with Multiple Parameters of Disease Measurement

FREMONT, Calif., November 30, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today reported top level results of its Phase I/II clinical trial with ABX-IL8, a fully human antibody developed with the company's XenoMouse™ technology. Additional details will be presented at the Psoriasis: from Gene to Clinic meeting in London on December 2,1999. The multi-center, placebo controlled trial involved 45 patients with moderate to severe psoriasis. Abgenix reported that ABX-IL8 was safe and well tolerated at all dose levels tested and that a dose-dependent improvement was seen in multiple measures of disease. These efficacy measures included psoriasis area severity index (PASI), total body surface area (BSA), Physician's Global Assessment (PGA), and plaque photographs. The company also indicated that it plans to initiate a Phase II clinical trial in psoriasis during the first half of 2000. Other inflammatory disease indications including rheumatoid arthritis continue to be evaluated.

PASI analysis is a widely accepted measure of drug response in psoriasis patients. Fifty-eight percent (58%) of the patients who received ABX-IL8 1.0 mg/kg and 3.0 mg/kg, administered once every three weeks for four consecutive doses, achieved a >25% improvement, and 21% of patients achieved a >50% improvement in PASI score. This compared favorably to patients receiving 0.3 mg/kg ABX-IL8 (20% of patients achieved a >25% improvement and 0% a >50% improvement) and to patients receiving placebo (0% of patients with improvement of >25%). BSA and PGA measures and plaque photographs also showed dose dependent improvement.

"The Phase I/II trial of ABX-IL8 was primarily designed to demonstrate safety so it is a nice surprise to see such encouraging results on efficacy parameters," stated R. Scott Greer, president and CEO of Abgenix. "We will be optimizing the dose and regimen of ABX-IL8
'"/>

Contact: Kurt Leutzinger, Abgenix
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
8. Scientists question reports of massive ant supercolonies in California and Europe
9. Survey reports fall in stem cell transplants for breast cancer
10. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
11. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Abgenix reports positive clinical data with ABX Psoriasis

(Date:7/31/2014)... the Rim Fire was in full fury, raging swiftly ... entered the backcountry of Yosemite National Park in California,s ... park, the battle began to turn, enacting a case ... combine to fuel large, severe fires. , "When the ... where fire had been used as a management tool, ...
(Date:7/31/2014)... or fat cells, are inherently different. Each of these ... own role in metabolism. In the human body, white ... primary function is energy storage. On the other hand, ... are only found in a few places in the ... type of brown adipocytes, appear mixed with brown adipocytes ...
(Date:7/31/2014)... nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and ... British Medical Journal Open (BMJ Open) (i) and ... article looked at the effects of tree nuts ... nut consumption resulted in a significant decrease in triglycerides ... article focused on the effect of tree nuts on ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Hope for the overweight 2New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2
(Date:7/31/2014)... through organs and even the entire body to visualize ... structures has been a long-time dream of biologists. A ... in the journal Cell has now made ... opaque organs, bodies, and human tissue biopsies transparent, while ... could pave the way for a better understanding of ...
(Date:7/31/2014)... York , July 31, 2014 ... Transparency Market Research "Quantum Dots Market - Global Industry ... 2023," the market was valued at USD 88.5 million ... million by 2023, growing at a CAGR of 53.8% ... Quantum Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html ...
(Date:7/31/2014)... York , July 31, 2014 ... Transparency Market Research "Electrodes for Medical Devices Market (Diagnostic ... Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and ... Trends and Forecast, 2013 - 2019," the global electrodes ... million in 2012 and is estimated to reach a ...
(Date:7/31/2014)...  Smith & Nephew (LSE:SN, NYSE: ... announced its entry into the forefoot market with ... System. Comprised of three separate repair options, the ... repair and reconstruction, a metatarsal osteotomy guide, and ... fusion, also known as hammer toe correction. ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4
Cached News: